3-(2,6-dimethyl phenylcarbamoyl) 5-methoxymethyl isoxazole | 139297-30-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,6-dimethyl phenylcarbamoyl) 5-methoxymethyl isoxazole
• 英文别名: 3-(2,6-dimethyl phenylcarbamoyl)-5-methoxymethyl isoxazole；3-Isoxazolecarboxamide, N-(2,6-dimethylphenyl)-5-(methoxymethyl)-；N-(2,6-dimethylphenyl)-5-(methoxymethyl)-1,2-oxazole-3-carboxamide
• CAS: 139297-30-6
• 化学式: C₁₄H₁₆N₂O₃
• 分子量: 260.293
• InChiKey: WLSAOSVINKQXIG-UHFFFAOYSA-N

物化性质

• 沸点：
  331.7±42.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-二甲基苯胺 在 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 以46%的产率得到3-(2,6-dimethyl phenylcarbamoyl) 5-methoxymethyl isoxazole
  参考文献：
  名称：

  N(pyrazol-3-yl) benzamides and pharmaceutical compositions

  摘要：

  本发明涉及用于治疗癫痫的化合物，选自具有以下通式的化合物：##STR1## 其中，R.sub.1 是C.sub.1 -C.sub.4烷基，R.sub.2 是C.sub.1 -C.sub.4烷基，R.sub.3 选自氢、C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基和C.sub.1 -C.sub.4羟基烷基，R.sub.4 选自氢、C.sub.1 -C.sub.4烷基、C.sub.2 -C.sub.7烷酰基和C.sub.1 -C.sub.4羟基烷基。

  公开号：

  US05464860A1

文献信息

• 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure
  申请人：Novapharme

  公开号：US05258397A1

  公开（公告）日：1993-11-02

  The object of the invention is heterocyclic compounds of general formula (I) endowed with anticonvulsant activity: ##STR1## in which Y is selected from --O--, --S-- and ##STR2## R.sub.4 being H or optionally substituted alkyl, acyl or benzyl, Z is selected from the groups --CO--N(R.sub.6)--,--NH--CO--CH.dbd.CH-- and --N(R.sub.6)--CO, R.sub.6 being H or alkyl; R.sub.1 is C.sub.1 -C.sub.4 alkyl; R.sub.2 is C.sub.1 -C.sub.4 alkyl or halogen; R.sub.3 represents optionally substituted C.sub.1 -C.sub.4 alkyl, alkoxy or hydroxyalkyl, or C.sub.2 -C.sub.7 alkanoyl.

  本发明的对象是具有抗惊厥活性的通式(I)杂环化合物：##STR1## 其中Y选自--O--, --S--和##STR2## R.sub.4为H或可选地取代的烷基、酰基或苄基，Z选自--CO--N(R.sub.6)--, --NH--CO--CH.dbd.CH--和--N(R.sub.6)--CO组，R.sub.6为H或烷基；R.sub.1为C.sub.1 -C.sub.4烷基；R.sub.2为C.sub.1 -C.sub.4烷基或卤素；R.sub.3代表可选地取代的C.sub.1 -C.sub.4烷基、烷氧基或羟基烷基，或C.sub.2 -C.sub.7烷酰基。
• New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents
  作者：F Lepage、F Tombret、G Cuvier、A Marivain、JM Gillardin

  DOI：10.1016/0223-5234(92)90137-p

  日期：1992.9

  We prepared a series of N-aryl isoxazolecarboxamide, N-isoxazolylbenzamide compounds and derivatives and studied their anticonvulsant action in MES and MMS tests. Some of these reveal considerable activity, especially with respect to MES test. The disubstitution in the 2.6-position on the phenyl ring by two methyl groups would appear to be of primary importance for the activity. The amide bridge between the phenyl and isoxazolic rings, whether of the anilide or benzamide type, seems to show similar anticonvulsant behavior. We have selected the derivatives 8 (N-(2.6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide, 12 (N-(2,6-dimethylphenyl)-5-hydroxymethyl-3-isoxazolecarboxamide) and 51 (N-(5-methyl-3-isoxazolyl)-2.6-dimethylbenzamide) which are presently being studied in more extended pharmacological tests.
• US5258397A
  申请人：——

  公开号：US5258397A

  公开（公告）日：1993-11-02
• US5464860A
  申请人：——

  公开号：US5464860A

  公开（公告）日：1995-11-07
• N(pyrazol-3-yl) benzamides and pharmaceutical compositions
  申请人：Novapharme

  公开号：US05464860A1

  公开（公告）日：1995-11-07

  The invention relates to a compound useful for treating epilepsy selected from the compounds of the general formula: ##STR1## in which R.sub.1 is C.sub.1 -C.sub.4 alkyl, R.sub.2 is C.sub.1 -C.sub.4 alkyl, R.sub.3 is selected from hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and C.sub.1 -C.sub.4 hydroxyalkyl, and R.sub.4 is selected from hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.7 alkanoyl and C.sub.1 -C.sub.4 hydroxyalkyl.

  本发明涉及用于治疗癫痫的化合物，选自具有以下通式的化合物：##STR1## 其中，R.sub.1 是C.sub.1 -C.sub.4烷基，R.sub.2 是C.sub.1 -C.sub.4烷基，R.sub.3 选自氢、C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基和C.sub.1 -C.sub.4羟基烷基，R.sub.4 选自氢、C.sub.1 -C.sub.4烷基、C.sub.2 -C.sub.7烷酰基和C.sub.1 -C.sub.4羟基烷基。